JANX
Janux Therapeutics Inc.
Company Overview
| Mkt Cap | $1.59B | Price | $28.71 |
| Volume | 911.78K | Change | +0.70% |
| P/E Ratio | -23.1 | Open | $28.10 |
| Revenue | $10.6M | Prev Close | $28.51 |
| Net Income | $-69.0M | 52W Range | $21.73 - $71.71 |
| Div Yield | N/A | Target | $81.20 |
| Overall | 63 | Value | 60 |
| Quality | 63 | Technical | 66 |
No chart data available
Stock Overview
Updated DailyJanux Therapeutics Inc. (JANX) is a leading Professional, Scientific, and Technical Services company in the Research and Development in Biotechnology industry, currently trading at $28.71 with a market capitalization of $1.59 billion. The stock is approaching its 52-week lows, suggesting potential value opportunity, demonstrating unrated quality characteristics with a MarketXLS quality score of N/A.
Today's trading session shows JANX with a volume of 912K shares. The stock opened down 1.44% from yesterday's close of $28.51. Current analyst estimates project earnings of $-2.37 per share for this year, with next year targeting $-3.24.
JANX demonstrates very strong technical momentum based on technical analysis. The company trades on the NSD exchange and operates alongside industry peers including OTIC, OTLC, OVAT-CA, ORTH-CA.
Key investment considerations for JANX include strong overall investment metrics. The company offers a dividend yield of NA% and analyst price targets suggest potential upside of 182.8%. The stock shows fair valuation metrics based on valuation analysis.
Analysis generated on November 3, 2025 at 04:51 AM
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | JANX | $28.71 | +0.7% | 911.78K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |